Physician profile
David Seiter
NPI 1891190567
$194,224.18
in general payments reported to CMS, 2019-2025
38 companies · $144K in 2025
The $144K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,813 · 2022: $3,282 · 2023: $17K · 2024: $26K · 2025: $144K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $128K · Food and Beverage: $24K · Consulting Fee: $19K · Travel and Lodging: $17K · Education: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $128,276.50 |
| Food and Beverage | $24,317.68 |
| Consulting Fee | $18,572.60 |
| Travel and Lodging | $16,607.94 |
| Education | $354.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $46,043.81 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $40,730.95 | 2021-2025 | Nemluvio, Aklief |
| Ucb, INC. | $39,396.41 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $37,465.53 | 2021-2025 | |
| Incyte Corporation | $6,768.09 | 2021-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $6,166.69 | 2023-2025 | Zoryve |
| Abbvie INC. | $4,345.09 | 2021-2025 | |
| Leo Pharma INC. | $2,072.70 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $1,936.41 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $1,566.58 | 2021-2025 | Blu-U, Odomzo, Winlevi |
| Lilly USA, LLC | $1,566.56 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $1,386.16 | 2021-2025 | |
| Pfizer INC. | $1,221.54 | 2021-2025 | |
| Amgen INC. | $656.46 | 2021-2025 | Otezla, Otezla, Enbrel |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $544.30 | 2021-2025 | Jublia, Arazlo, Siliq |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Seiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.